GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. - Wikidata - awgldk - TriplyDB

GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.

GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.

http://www.wikidata.org/entity/Q34397451

about

Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect Pathways and therapeutic targets in melanoma Treg functional stability and its responsiveness to the microenvironment The Ikaros family of zinc-finger proteins Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study Molecular pathways and therapeutic targets in lung cancer Ubiquitous points of control over regulatory T cells.Increased antigen presentation but impaired T cells priming after upregulation of interferon-beta induced by lipopolysaccharides is mediated by upregulation of B7H1 and GITRL Expansion of regulatory GITR+CD25 low/-CD4+ T cells in systemic lupus erythematosus patients.Glucocorticoid-induced tumour necrosis factor receptor-related protein: a key marker of functional regulatory T cells.Immune based therapy for melanoma Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma.Instability of Helios-deficient Tregs is associated with conversion to a T-effector phenotype and enhanced antitumor immunity Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer.Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?The head and neck cancer immune landscape and its immunotherapeutic implications.MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy Ptpn22 Modifies Regulatory T Cell Homeostasis via GITR Upregulation.Regulator Versus Effector Paradigm: Interleukin-10 as Indicator of the Switching Response.Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy.Roles of regulatory T cells in cancer immunity.Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment.Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy.Immune Checkpoint Blockers and Ovarian Cancer.Enhanced immunotherapy by combining a vaccine with a novel murine GITR ligand fusion protein.TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines.Constitutive expression of NF-κB inducing kinase in regulatory T cells impairs suppressive function and promotes instability and pro-inflammatory cytokine production.T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity.Immune checkpoints, their control by immunotherapy and ovarian cancer.Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4+ T cells combined with agonist α-GITR mAb promotes durable CD8+ T-cell-dependent antitumor immunity.Anti-GITR therapy promotes immunity against malignant glioma in a murine model.A positive-feedback loop between tumour infiltrating activated Treg cells and type 2-skewed macrophages is essential for progression of laryngeal squamous cell carcinoma.Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity Immune Checkpoint Inhibition in Head and Neck Cancer

P2860

Q26765459-96FED79A-02A4-4FFD-9831-316798A756A8 Q26775578-3D848A05-F407-4FAD-AA74-186CEEA4BA26 Q26865736-29EB8AD1-CDCA-464D-B4AA-3E120E1D3E0E Q27008946-4CAAC622-4A26-4BE2-9964-73F9EF6F7FC5 Q28066194-72589D4F-C06B-49EB-A3AA-F2BD7C194B20 Q28084489-306D83F6-17D8-470A-95DF-D054E2A11A89 Q33688872-F03697B9-B8E8-4AE6-933B-609F9AEE4928 Q33850593-D26E5274-8A54-4626-92B3-FC771E15D3A7 Q34075613-8FF4555F-17F9-464E-8286-CC1A738EB8A4 Q34401977-8B9B5503-F19D-4F31-80E9-74FD80F08667 Q35551328-A9DB26FB-0EC5-43F3-B3DE-2E29C7F8E0D7 Q36876757-22D2E1CD-6F8E-4956-A86F-8D670EAF3BCF Q36907372-749A286D-FB06-4828-9C83-156944094167 Q36978175-07727701-F9EE-4517-AB1E-BB95DDFCB4F6 Q37017190-89ED79D6-0ACF-4609-BA1D-7ADAFB5AD00E Q37114367-5C2675C2-5FB8-4028-B908-920848985692 Q37351606-344D489C-4EA5-4C76-A8CD-D1D31E58FF72 Q37741582-A59452AA-FA06-4E7A-867A-96274205AC2D Q38214095-30FF0745-CE91-4C1C-9C5A-78E443165F0F Q38576971-2A98DE2A-D000-4777-965B-AD9B1F4ED417 Q38602859-7237B909-C708-4ED4-8709-ECE51115307A Q38770814-346C7AFE-2080-447F-815F-56E92E6E409A Q38775177-058DC56E-2BA7-4C10-97CB-E8AC381F7095 Q38779877-80BB01C5-745A-46C4-B04C-4054300DDE5D Q38830072-07AA5A47-6046-48CA-8290-251F88F66225 Q39189908-D6BF98E8-1418-42E6-8896-2CABF4DC344B Q40066040-A0DE633A-234B-44AC-9F8F-41BA92837F26 Q41412439-0BC4B1EF-399F-4B73-87C3-0E760E1A4623 Q41601825-6CC4FAB6-30E8-477F-B8AC-FD60DF30EA25 Q44302880-F0E3DFDB-D9AF-4F6C-B490-2FE752B59ED7 Q45064262-909CEC05-C7D5-4714-B714-F60A068B7B73 Q47094157-9B9A9375-40BE-4DE4-B2FC-498AEDC9EDCB Q47132997-5987B9DF-1363-4EB0-BFF4-15D4E7C0F953 Q47143437-07D608DE-8065-4EA3-A8A8-3A7ADBA85AFA Q47325431-D1A70350-56FF-40CA-8D81-2AE8F34952D3 Q48170351-D68B66CF-A542-461C-8411-A6BD9A537BFF Q48480477-871C8A20-98F9-4A03-B45A-480928AE53BA Q49823387-1A88991B-7CE9-4367-9E9C-1EE91E8F8392 Q57160066-B55FC3D6-C2EE-4D7B-94C9-39DB97CE6843 Q58694216-FECC1050-6B39-4F44-8219-1F3CEDECD8DC

P2860

GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.

http://www.wikidata.org/entity/Q34397451

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

GITR pathway activation abroga ...... tory T cell lineage stability.

@ast

GITR pathway activation abroga ...... tory T cell lineage stability.

@en

GITR pathway activation abroga ...... tory T cell lineage stability.

@nl

type

label

GITR pathway activation abroga ...... tory T cell lineage stability.

@ast

GITR pathway activation abroga ...... tory T cell lineage stability.

@en

GITR pathway activation abroga ...... tory T cell lineage stability.

@nl

prefLabel

GITR pathway activation abroga ...... tory T cell lineage stability.

@ast

GITR pathway activation abroga ...... tory T cell lineage stability.

@en

GITR pathway activation abroga ...... tory T cell lineage stability.

@nl

P1433

Q34397451-071FBA61-08BA-442D-AD0F-545D53B08E20

P1476

Q34397451-B0564329-25D0-44C3-A5FB-96D2366C395F

P2093

Q34397451-0275D4CB-67EA-482B-9E8C-0227C96CE28B

Q34397451-068570FC-C803-4891-9B7E-0E074CD06A2C

Q34397451-25EC60D2-7298-42CB-AE19-6D8CF1547B69

Q34397451-367B9C12-82F5-4F2F-B770-B1AAC1ED4E18

Q34397451-586E7DD4-B5DD-43CD-A50D-62FEC8D62431

Q34397451-5883DDAF-4AC7-43FD-981E-B74DB547C5E1

Q34397451-73BCB353-4A1D-4503-A2FD-9200F8C67220

Q34397451-7930981B-1C10-4D04-B38B-4AA86C16AABD

Q34397451-79C50310-226D-4D9F-9AA3-4C906E0C844D

Q34397451-7C2E919A-BE82-49BB-B702-82CF80F817F0

P2860

Q34397451-043BB2D2-7DF7-4868-A56F-921E1918C1F6

Q34397451-0BD5B11C-6AFA-4689-9DAD-C7D12DAABC28

Q34397451-1F1FD8A5-754A-40FE-82AA-20A19C0D329B

Q34397451-21571B77-D9F5-439C-A645-2987B1BCED0F

Q34397451-2A180718-D47A-4319-BD90-CB24B04DEFEF

Q34397451-2CDAE0B9-5367-4357-8BB9-94A48107A2F3

Q34397451-38320880-B83C-4CB8-B931-2433716B0F5D

Q34397451-3C36C08A-512D-487A-BFD7-6747AA42C381

Q34397451-42527CAE-45C8-408C-B1F4-0CB4A5F63B0E

Q34397451-4C671402-88DB-4F2E-8EB7-0A014A33CD6F

P304

Q34397451-0307B54A-20A2-433D-AF02-D0E2807E4B24

P31

Q34397451-A430FD74-0AC3-4109-BBAD-21AA7436E041

P356

Q34397451-499DD892-77D8-4994-8B8B-5EA8C1B30BA4

P433

Q34397451-D3B0635D-7BB5-410B-9809-7375EE2AAC73

P478

Q34397451-DC8D842E-124C-4F72-A67A-216981C5D94E

P577

Q34397451-7D1905EE-1D5E-4A01-8B45-4A110B3E95B9

P698

Q34397451-9BEDB626-22BE-4B53-8741-320F29B89353

P932

Q34397451-7C3B4593-4BE3-4921-A725-2DF5134ACD00

P356

2326-6066.CIR-13-0086

P1433

Cancer immunology research

P1476

GITR pathway activation abroga ...... tory T cell lineage stability.

@en

P2093

Adam Cohen

http://www.w3.org/2001/XMLSchema#string

Alan N Houghton

http://www.w3.org/2001/XMLSchema#string

Cailian Liu

http://www.w3.org/2001/XMLSchema#string

Campbell Bryson

http://www.w3.org/2001/XMLSchema#string

David A Schaer

http://www.w3.org/2001/XMLSchema#string

Hong Zhong

http://www.w3.org/2001/XMLSchema#string

Jedd D Wolchok

http://www.w3.org/2001/XMLSchema#string

Nicole Malandro

http://www.w3.org/2001/XMLSchema#string

Sadna Budhu

http://www.w3.org/2001/XMLSchema#string

Taha Merghoub

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Modulation of GITR for cancer immunotherapy

Science gone translational: the OX40 agonist story

Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope

Nivolumab plus ipilimumab in advanced melanoma.

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

A function for interleukin 2 in Foxp3-expressing regulatory T cells

P304

320-331

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2326-6066.CIR-13-0086

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24416730

http://www.w3.org/2001/XMLSchema#string

P932

3885345

http://www.w3.org/2001/XMLSchema#string